In a patient with type 2 diabetes, HbA1c ≈ 7.4 %, fasting glucose ≈ 128 mg/dL, eGFR ≈ 45 mL/min (creatinine 1.6 mg/dL) who is taking dapagliflozin 10 mg daily and gliclazide 60 mg twice daily, what additional therapy should be added?

Add Metformin as the Foundation of Therapy

The most critical missing element in this patient's regimen is metformin, which should be added immediately unless contraindicated. With an eGFR of 45 mL/min, metformin can be safely initiated and is the preferred foundational therapy for type 2 diabetes. 1

---

Why Metformin Must Be Added First

Metformin is the cornerstone of type 2 diabetes management and should be continued even when other agents are added, including SGLT2 inhibitors and sulfonylureas. 1 The patient's current regimen lacks this essential foundation, which provides:

• Cardiovascular mortality benefit compared to sulfonylureas, with superior effects on A1C and weight 1
• Complementary mechanism to both dapagliflozin and gliclazide, working through improved insulin sensitivity rather than glucose excretion or insulin secretion 1
• Minimal hypoglycemia risk when used alone or with SGLT2 inhibitors 1

---

Metformin Dosing with eGFR 45 mL/min

Start metformin at 500 mg once or twice daily with meals, titrating gradually to minimize gastrointestinal side effects. 1 The patient's eGFR of 45 mL/min places them at the threshold where metformin requires careful monitoring but remains safe:

• Metformin is safe when eGFR ≥30 mL/min/1.73 m², and the FDA revised labeling to reflect this safety profile 1
• For eGFR 30–45 mL/min/1.73 m², there is increased risk for periodic decreases to ≤30 mL/min/1.73 m², requiring closer monitoring 1
• Target dose: Gradually increase to 1000 mg twice daily (2000 mg total) if tolerated and eGFR remains stable, as this provides maximal glucose-lowering effect 1
• Maximum safe dose: Do not exceed 2000 mg daily given the borderline eGFR 1

---

Addressing the Sulfonylurea Issue

Once metformin is established, strongly consider reducing or discontinuing gliclazide due to hypoglycemia risk, especially in the context of moderate renal impairment. 1, 2

• Sulfonylureas are the fourth leading cause of emergency room admissions due to drug side effects in patients >65 years old 1
• In patients with eGFR 45 mL/min, sulfonylureas carry increased hypoglycemia risk as renal clearance of both the drug and its metabolites is impaired 1
• Metformin plus dapagliflozin may provide adequate glycemic control without the hypoglycemia risk of gliclazide, allowing sulfonylurea discontinuation 1

---

Alternative Third Agent: GLP-1 Receptor Agonist

If HbA1c remains >7% after 3 months on metformin + dapagliflozin, add a GLP-1 receptor agonist rather than continuing gliclazide. 1, 2

• GLP-1 receptor agonists provide HbA1c reduction of 0.7–1.0% when added to existing therapy 1
• Cardiovascular benefit is proven in patients with established ASCVD or high cardiovascular risk 1
• Weight loss rather than weight gain, unlike sulfonylureas or insulin 1
• Minimal hypoglycemia risk when used without sulfonylureas or insulin 1, 2

Specific options include:

• Semaglutide 0.25 mg weekly subcutaneously, titrating to 0.5 mg after 4 weeks, then 1.0 mg if needed 1, 3
• Liraglutide 0.6 mg daily subcutaneously, increasing to 1.2 mg after 1 week, then 1.8 mg if needed 1, 3

---

Monitoring Strategy

Reassess HbA1c and renal function in 3 months after adding metformin. 1

• Check eGFR every 3–6 months given baseline eGFR of 45 mL/min to ensure metformin remains safe 1
• Monitor for vitamin B12 deficiency with long-term metformin use, especially if anemia or peripheral neuropathy develops 1
• If HbA1c remains ≥7.4% after 3 months, proceed to triple therapy by adding a GLP-1 receptor agonist and discontinuing gliclazide 1, 2

---

Critical Pitfalls to Avoid

• Do not delay metformin initiation due to borderline eGFR—it remains safe and beneficial at eGFR 45 mL/min 1
• Do not continue gliclazide long-term in a patient with moderate renal impairment when safer alternatives exist 1, 2
• Do not add insulin prematurely—the patient's HbA1c of 7.39% does not warrant insulin, and oral/injectable non-insulin agents should be optimized first 1
• Do not stop dapagliflozin—it provides cardiovascular and renal protection independent of glucose lowering and should be continued 1, 4, 5

---

Expected Outcomes

With metformin addition and gliclazide optimization:

• HbA1c reduction of 0.5–1.0% from metformin alone, potentially bringing HbA1c to 6.4–6.9% 1
• Improved cardiovascular risk profile from metformin's proven mortality benefit 1
• Reduced hypoglycemia risk if gliclazide is discontinued or reduced 1, 2
• Preserved renal function from continued dapagliflozin use 4, 5